ArticleTrials2018

Dedicated mobile application for drug adverse reaction reporting by patients with relapsing remitting multiple sclerosis (Vigip-SEP study): study protocol for a randomized controlled trial.

Gilles Defer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.